Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

Neurocrine Biosciences (NBIX) executives will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026.

Rhea-AI Summary

Neurocrine Biosciences (NBIX) executives will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026. The presentation is scheduled for 3:30 p.m. Greenwich Mean Time (10:30 a.m. Eastern Time). A webcast will be accessible through the Investors section of the company's website, with a replay available approximately one hour after the event concludes and archived for approximately one month.

Key Terms

tardive dyskinesia, chorea, classic congenital adrenal hyperplasia, hyperphagia, +2 more

6 terms

tardive dyskinesia medical

"FDA-approved treatments for tardive dyskinesia"

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

chorea medical

"chorea associated with Huntington's disease"

Chorea is a neurological condition that causes sudden, irregular, involuntary movements—like fragments of a dance you can’t control—that can affect the face, limbs, or trunk. It matters to investors because chorea can drive demand for treatments, influence clinical trial design and regulatory decisions, and signal safety or liability risks for companies developing therapies or diagnostics, all of which affect potential market size and financial outlooks.

classic congenital adrenal hyperplasia medical

"classic congenital adrenal hyperplasia"

A genetic disorder present at birth in which the adrenal glands cannot make the right balance of hormones, usually because a key enzyme is missing, leading to low stress and salt-regulating hormones and excess sex hormones; it can cause dehydration and abnormal genital development in newborns. Investors care because the condition requires lifelong management, newborn screening and specialized drugs or tests, so advances in therapies, diagnostics or gene treatments can create durable markets and regulatory milestones.

hyperphagia medical

"hyperphagia in patients with Prader-Willi syndrome"

An abnormally strong, persistent urge to eat that leads to excessive food intake beyond normal hunger; it can be a symptom of neurological, hormonal, genetic, or psychiatric conditions. Investors care because therapies that reduce hyperphagia can become measurable drug trial endpoints, define patient populations and market size, and influence regulatory approval, reimbursement prospects and commercial potential in the obesity and rare-disease sectors.

endometriosis medical

"endometriosis and uterine fibroids"

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. It can impact a person's health and quality of life, potentially leading to increased healthcare costs and affecting workforce productivity. For investors, understanding conditions like endometriosis highlights the importance of healthcare innovations and markets related to women's health.

uterine fibroids medical

"endometriosis and uterine fibroids"

Uterine fibroids are noncancerous growths that develop in the muscular wall of the uterus, often described like small rubbery lumps within the organ. They matter to investors because they affect a large number of people of reproductive age and drive demand for diagnostics, medications, minimally invasive procedures and surgical devices, creating revenue opportunities and regulatory, reimbursement and competitive considerations for healthcare companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare Conference in London at 3:30 p.m. Greenwich Mean Time (10:30 a.m. Eastern Time) on November 17, 2026.

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-2026-jefferies-global-healthcare-conference-302935443.html

SOURCE Neurocrine Biosciences, Inc.